<DOC>
	<DOCNO>NCT03068780</DOCNO>
	<brief_summary>This Phase III , Efficacy Safety Study Oleogel-S10 Participants Inherited Epidermolysis Bullosa ( EB ) . EB rare group genetic skin fragility disorder characterise blister skin response minor injury . In case , onset EB birth shortly . All participant affect type EB share main characteristic repeatedly develop painful wound take day month heal . Current treatment EB primarily preventative supportive include protection mechanical force avoid rubbing , early treatment wound prevent infection , protection wound adequate non-adhesive dressing enable heal . Oleogel-S10 authorised 2016 European Union treatment partial thickness wound adult brand name Episalvan® . The active pharmaceutical ingredient Oleogel-S10 refine birch bark extract , quantify 72 88 % betulin . This clinical study Oleogel-S10 patient inherit EB initiated investigate whether Oleogel-S10 effective treatment EB wound safe long term use . Oleogel-S10 compare vehicle gel placebo . The placebo identical look sunflower oil gel contain active substance . The participant receive either Oleogel-S10 vehicle gel double-blind study phase 90 day . The probability participant receive Oleogel-S10 50 % , mean 1 2 chance receive Oleogel-S10 . However , follow-up phase study participant treat Oleogel S10 period 24 month . This clinical study perform several countries; total , 164 participant expect participate .</brief_summary>
	<brief_title>Phase III Efficacy Safety Study Oleogel-S10 Epidermolysis Bullosa</brief_title>
	<detailed_description />
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<criteria>Male female patient subtype inherit EB include EB simplex ( EBS ) , junctional EB ( JEB ) , dystrophic EB ( DEB ) , Kindler syndrome age ≥4 year , Patients EB target wound ( i.e. , EB partial thickness wind 10 cm² 50 cm² size age ≥21 day ) , Patient and/or his/her legal representative has/have inform , has/have read understood patient information/informed consent form , has/have give write informed consent , Patient and/or his/her legal representative must able willing follow study procedure instruction . EB target wind clinical sign local infection , Use systemic antibiotic woundrelated infection within 7 day prior enrolment , Administration systemic topical steroid ( except inhale , ophthalmic topical application , budesonide suspension oesophageal strictures [ e.g. , Pulmicort respules® 0.25 mg/2 mL 0.5 mg/2 mL ] ) within 30 day enrolment , Immunosuppressive therapy cytotoxic chemotherapy within 60 day prior enrolment , Patient undergone stem cell transplant gene therapy treatment inherit EB , Current and/or former malignancy include basal cell carcinomas squamous cell carcinoma , Enrolment interventional study treat investigational drug disease within 4 week prior study entry , Factors present patient and/or his/her legal representative could interfere study compliance inability attend schedule study visit compliance home dressing change , Pregnant nurse woman woman childbearing potential include postmenarchal female adolescent willing use effective form birth control failure rate &lt; 1 % per year ( e.g. , implant , injectable , combined oral contraceptive , intrauterine contraceptive device , sexual abstinence , vasectomised partner ) participation study ( least 3 month thereafter ) , Patient member investigational team his/her immediate family , Patient live household study participant .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>